Drugs that contain Trametinib Dimethyl Sulfoxide

1. List of Mekinist drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7378423 NOVARTIS Pyrimidine compound and medical use thereof
May, 2027

(4 years from now)

US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof
Jun, 2025

(2 years from now)

US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Oct, 2030

(7 years from now)

US9271941 NOVARTIS Pharmaceutical composition
Jan, 2032

(8 years from now)

US9155706 NOVARTIS Pharmaceutical composition
Jan, 2032

(8 years from now)

US8580304 NOVARTIS Pharmaceutical composition
Jan, 2032

(8 years from now)

US9399021 NOVARTIS Pharmaceutical composition
Jan, 2032

(8 years from now)

US10869869 NOVARTIS Method of adjuvant cancer treatment
Aug, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 22, 2024
M Oct 6, 2022
New Indication (I) Jun 22, 2025

Market Authorisation Date: 29 May, 2013

Treatment: Mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test; Treatment of unresectable or metastatic melanoma; Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; In combination with dabrafenib for the treatment of unresectable or metastatic melanoma.; Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; Mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Mekinist(r) is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Mekinist in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in